Scarica l'app Stockscreener
0.2182
4.45%
0.0093
Dopo l'orario di chiusura:
.22
0.0018
+0.82%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché MBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.2089
Aprire:
$0.2277
Volume 24 ore:
37.41M
Relative Volume:
5.35
Capitalizzazione di mercato:
$10.83M
Reddito:
-
Utile/perdita netta:
$-40.10M
Rapporto P/E:
-0.0496
EPS:
-4.4
Flusso di cassa netto:
$-36.99M
1 W Prestazione:
+18.65%
1M Prestazione:
+18.72%
6M Prestazione:
-55.15%
1 anno Prestazione:
-83.34%
Intervallo 1D:
$0.2113
$0.2476
Intervallo di 1 settimana:
$0.162
$0.4389
Portata 52W:
$0.1281
$1.53
Mustang Bio Inc Stock (MBIO) Company Profile
Nome
Mustang Bio Inc
Settore
Industria
Telefono
(781) 652-4500
Indirizzo
377 PLANTATION STREET, WORCESTER, NY
Confronta MBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBIO
Mustang Bio Inc
|
0.2182 | 10.83M | 0 | -40.10M | -36.99M | -4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mustang Bio Inc Stock (MBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-18 | Iniziato | BTIG Research | Buy |
| 2020-10-02 | Iniziato | B. Riley FBR | Buy |
| 2019-11-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-08-13 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Mustang Bio Inc Borsa (MBIO) Ultime notizie
Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off - Asianet Newsable
Stock market news: Neumora Therapeutics down by 80.75% while N2OFF surged by 333.47% during mid day trading - Business Upturn
Mustang Bio files to sell 34.77M shares of common stock for holders - MSN
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
Mustang Bio Inc Still Hasn’t Convinced Analysts? - Stocks Register
Likelihood of Approval and Phase Transition Success Rate ModelMB-108 in Recurrent Malignant Glioma - GlobalData
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Mustang Bio faces delisting, appoints new interim CFO - Investing.com
Mustang Bio's Interim CFO Resigns After 10 Months - MarketWatch
Mustang Bio Faces Nasdaq Delisting and Leadership Changes - TipRanks
Mustang Bio, Inc. Announces CFO Changes - Marketscreener.com
ARMISTICE CAPITAL, LLC Acquires New Stake in Mustang Bio Inc - GuruFocus.com
Fortress Biotech Inc. (FBIOP) Quarterly 10-Q Report - Quartzy
Mustang Bio gets extension for Nasdaq compliance By Investing.com - Investing.com South Africa
Crude Oil Brent (F) (QAX25) Quote - The Globe and Mail
Mustang Bio gets extension for Nasdaq compliance - Investing.com
Mustang Bio Receives Positive Listing Determination from Nasdaq - The Manila Times
Mustang Bio Secures Critical Nasdaq Extension, Faces January 2025 Deadline for $1 Compliance | MBIO Stock News - StockTitan
Virus Therapy Gets Orphan Drug Designation for Glioma Treatment - www.oncnursingnews.com/
Mustang Bio Inc (MBIO) Quarterly 10-Q Report - Quartzy
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment - Yahoo Finance
Toll Brothers Inc (TOL-N) QuotePress Release - The Globe and Mail
Mustang Bio gains FDA Orphan Drug Status for glioma treatment - Investing.com India
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for - GlobeNewswire
Mustang Bio gains FDA Orphan Drug Status for glioma treatment By Investing.com - Investing.com UK
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma - Yahoo Finance
Mustang Bio sets annual meeting date, deadlines for proposals - Investing.com
Everquote Inc Cl A (EVER-Q) QuotePress Release - The Globe and Mail
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Mustang Bio Secures $4M through Strategic Warrant Agreement - Yahoo Finance
Revance Therapeutics Inc’s (RVNC) Stock Is Harder To Predict Than You Think - Stocks Register
Mustang Bio, Inc. Appoints David Jin as A Member of the Board - Marketscreener.com
Mustang Bio secures $4 million from warrant exercises - Investing.com India
Mustang Bio secures $4 million from warrant exercises By Investing.com - Investing.com South Africa
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds - GlobeNewswire
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Benzinga
FDA Approves Ion Torrent Oncomine Dx Target for Brain Cancer - www.oncnursingnews.com/
Chimeric Antigen Receptor T (CAR-T) Cells Market Research Analysis 2024-2033 | Growth, Size, Analysis, Insi... - WhaTech
Investor’s Toolkit: Key Ratios for Assessing Mustang Bio Inc (MBIO)’s Performance - The Dwinnex
A stock that deserves closer examination: Mustang Bio Inc (MBIO) - US Post News
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - MSN
Mustang Bio Inc (MBIO) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
There is no doubt that Mustang Bio Inc (MBIO) ticks all the boxes. - SETE News
Mustang Bio Inc Azioni (MBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):